Silvercrest Asset Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Silvercrest Asset Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$722K	Hold	4,560	–	–	﹤0.01%	657
2026 Q1	$582K	Sell	4,560 -300	-6%	-$37.5K	﹤0.01%	663
2025 Q4	$593K	Hold	4,860	–	–	﹤0.01%	696
2025 Q3	$487K	Sell	4,860 -500	-9%	-$45K	﹤0.01%	700
2025 Q2	$445K	Sell	5,360 -225	-4%	-$17.9K	﹤0.01%	724
2025 Q1	$453K	Sell	5,585 -350	-6%	-$31.3K	﹤0.01%	717
2024 Q4	$535K	Buy	5,935 +100	+2%	+$9.69K	﹤0.01%	681
2024 Q3	$576K	Hold	5,835	–	–	﹤0.01%	635
2024 Q2	$541K	Hold	5,835	–	–	﹤0.01%	705
2024 Q1	$554K	Buy	5,835 +10	+0.2%	+$928	﹤0.01%	691
2023 Q4	$520K	Hold	5,825	–	–	﹤0.01%	658
2023 Q3	$425K	Hold	5,825	–	–	﹤0.01%	700
2023 Q2	$485K	Hold	5,825	–	–	﹤0.01%	680
2023 Q1	$444K	Buy	+5,825	New	+$483K	﹤0.01%	667

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Silvercrest Asset Management's XBI Position: Q2 2026 in Review

Silvercrest Asset Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 4,560 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Silvercrest Asset Management first reported a position in XBI in Q1 2023 and has held it in 14 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Silvercrest Asset Management held 4,560 shares of State Street SPDR S&P Biotech ETF worth $722K as of Q2 2026.
Silvercrest Asset Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Silvercrest Asset Management's portfolio in Q2 2026, its #657 holding.
Silvercrest Asset Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2023 and has held it in 14 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Silvercrest Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.